Age alone is not a barrier to concurrent chemoradiotherapy for advanced head and neck cancer
The Annals of otology, rhinology, and laryngology(2021)
摘要
Objectives To evaluate the benefits imparted by concurrent
chemoradiotherapy (CCRT) and chemotherapy of any form to elderly head
and neck cancer (HNC) patients in Ireland. Secondary outcomes included
comparison of these benefits to the adult population and subgroup
analysis by site. Design, setting, and participants A retrospective
cohort study was conducted using 20 years of cancer registry data
provided by the National Cancer Registry of Ireland. All HNC diagnosed
from 1994-2014 were included. Cox multivariate regression analysis was
applied to test for the benefits of CCRT and chemotherapy of any form in
HNC. The primary outcome measures were cancer-specific and all-cause
survival in months. Results Survival analysis showed an overall benefit
to the use of CCRT in patients with advanced disease over 65 years,
particularly when used for hypopharyngeal, oral cavity, oropharyngeal,
and laryngeal malignancy, though the latter did not achieve statistical
significance. Chemotherapy of any form conferred a survival benefit in
elderly patients with hypopharyngeal, laryngeal, nasopharyngeal, and
oropharyngeal cancer. Conclusion CCRT and chemotherapy of any form
confer significant survival benefits to appropriately selected elderly
HNC patients and should therefore not be withheld solely on the basis of
age.
更多查看译文
关键词
chemotherapy,concurrent chemoradiotherapy,elderly,head and neck cancer,survival
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要